Skip to content

META Turkiye logo

Main menu
    • Hakkımızda
      • Vizyon, misyon ve değerler
      • Çeşitlilik, eşitlik ve kapsayıcılık
      • Liderlerimiz
      • Yönetim Ekibi
      • Yönetim Kurulu
    • Çevre, Toplum & Denetim
    • İlkelerimiz
    • Tedarikçiler
    • Medya
    • Basın bültenleri
    • Yatırımcı ilişkilerine genel bakış
    • SEC dosyalaması
  • Ekibimize katılın

Bize Ulaşın

Main menu

Organon site directory

  • Organon

    • Brazil
    • Canada  English  ·  French
    • Latin America
    • Mexico
    • USA
  • Organon

    • Austria
    • Belgium  Dutch  ·  English  ·  French
    • Bulgaria
    • Czech Republic
    • Denmark
    • Estonia
    • Finland
    • France
    • Germany
    • Hungary
    • Ireland
    • Italy
    • Latvia
    • Lithuania
    • Luxembourg  English  ·  French
    • Netherlands  Dutch  ·  English
    • Norway
    • Poland
    • Portugal
    • Romania
    • Russia
    • Serbia
    • Slovakia
    • Slovenia
    • Spain
    • Sweden
    • Switzerland  French  ·  German  ·  English
    • Ukraine  Ukrainian  · 
    • United Kingdom
  • Organon

    • Australia
    • Hong Kong, China
    • Indonesia
    • Japan
    • Malaysia
    • New Zealand
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Organon

    • Egypt
    • Israel
    • Jordan
    • KSA
    • Kuwait
    • Lebanon
    • Northwest Africa  French  ·  Arabic  ·  Turkey
    • Oman
    • South Africa
    • Turkey
    • UAE
View all locations and contact information

What can we help you find?

Search for:

Our commitment to privacy

In 2020, Organon & Co., Inc., Kenilworth, NJ, USA established a Privacy Office to develop and oversee a global privacy program for our operations around the world. Our program is based on four privacy values that provide the foundation for responsible engagement, interactions and use of information about people:

  • respect for individual privacy expectations,
  • building and preserving trust,
  • preventing privacy harms, and
  • compliance with the letter and spirit of privacy and data protection laws around the world.

Our privacy program is built on a platform of organizational accountability for privacy, stewardship of the data we use to operate our business, consistent global privacy practices and standards that carry on our tradition of upholding high ethical standards across our business practices, and ongoing oversight to ensure that we continue to respond to changes in privacy expectations as technology and our business continue to evolve. For more information about our program, please see the global privacy program section of our corporate responsibility report.

Our Approach to Privacy Trust

Since we believe that trust is a core privacy value and essential to our corporate mission to discover, develop and provide innovative products and services that save and improve lives around the world, our global privacy program strategy is centered on two primary goals that aim to drive trust in how we engage with people and how we access, use and transfer information about people around the world:



Title

META Turkiye logo

Şirket

  • Hakkımızda
  • Liderlerimiz
  • Çevre, Toplum & Denetim

Kaynaklar

  • Hasta kaynakları
  • Yatırımcı ilişkileri
  • Medya

Bizimle iletişime geçin

  • Bizimle iletişime geçin
  • İletişim bilgisi
  • Global Lokasyonlar
  • İleriye Dönük Açıklama
  • Çerez politikası
  • Gizlilik Politikası
  • KULLANIM ŞARTLARI
  • Site haritası
Telif hakkı © 2025 Organon şirketler grubuna aittir. Tüm hakları saklıdır.

You are leaving Organon.com

Cancel Continue Opens a new window

Forward-looking statement of Organon

This news release of Organon (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the recent global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2020 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov Opens a new window ).

No Duty to Update

The information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.

Decline Accept